Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

IBM’s Biomedical Analytics Platform Helps Doctors Personalise Treatment

Published: Tuesday, March 20, 2012
Last Updated: Tuesday, March 20, 2012
Bookmark and Share
Italy’s Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments.

IBM announced it has developed a unique biomedical analytics platform for personalized medicine that could enable doctors to better advise on the best course of medical treatment. This could lead to smarter and more personalized healthcare in a wide-range of areas, including cancer management, hypertension, and AIDS care.

Scientists from IBM Research are collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori, a major research and treatment cancer center in Italy, on the new decision support solution. This new analytics platform is being tested by the Institute’s physicians to personalize treatment based on automated interpretation of pathology guidelines and intelligence from a number of past clinical cases, documented in the hospital information system.

Selecting the most effective treatment can depend on a number of characteristics including  age, weight, family history, current state of the disease and general health.  As a result, more informed and personalized decisions are needed to provide accurate and safe care.

IBM’s latest healthcare analytics solution, Clinical Genomics (Cli-G), can integrate and analyze all available clinical knowledge and guidelines, and correlate it with available patient data to create evidence that supports a specific course of treatment for each patient. Developed at IBM Research - Haifa, the new prototype works by investigating the patient’s personal makeup and disease profile, and combines this with insight from the analysis of past cases and clinical guidelines. The solution may provide physicians and administrators with a better picture of the patient-care process and reduce costs by helping clinicians choose more effective treatment options.

“Making decisions in today’s complex environment requires computerized methods that can analyze the vast amounts of patient information available to ease clinical decision-making,” notes Dr. Marco A. Pierotti, Scientific Director at the Istituto Nazionale dei Tumori. “By providing our physicians with vital input on what worked best for patients with similar clinical characteristics, we can help improve treatment effectiveness and the final patient outcome.”

Founded in 1925, the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is recognized as a scientific research and treatment institution in the field of pre-clinical and clinical oncology. The Institute’s special status as a research center enables it to transfer research results directly to clinical care. The Institute initiated this collaboration with IBM to enhance patient care through better use of innovative IT solutions. Once physicians make a diagnosis, they will receive personalized insights for their patients, based on medical information, automated interpretation of pathology clinical guidelines, and intelligence from a number of past clinical cases, documented in the hospital information system.

In addition to supporting decision-making about treatment, it can provide administrators at Fondazione IRCCS Istituto Nazionale dei Tumori with an aggregated view of patient care, enabling them to evaluate performances and using this knowledge to streamline processes for maximum safety. For example, hospital administrators can drill down into the data to better understand what the guidelines were for insights, what succeeded, and whether treatment quality has improved.

“Our clinical genomics solution may enable care-givers to personalize treatment and increase its chances of success,” explains Haim Nelken, senior manager of integration technologies at IBM Research - Haifa. “The solution is designed to provide physicians with recommendations that go beyond the results of clinical trials. It may allow them to go deeper into the data and more accurately follow the reasoning that led to choices previously made on the basis of subjective memory, intuition, or clinical trial results.”

Any patient data securely collected from hospitals and health organizations is ‘de-identified’ or made anonymous through the removal of personal identifying details. The IBM system does not need to know which individuals the information came from in order to draw conclusions. It works by identifying similar cases based on age, sex, symptoms, diagnosis, or other related factors.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.
Thursday, October 24, 2013
New Silicon Probe Assists in Disease Diagnostics and Drug Discovery
Scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately, reducing the need for large biopsy samples.
Monday, January 16, 2012
IBM and University Researchers to Develop Research Tools to Improve Cancer Patient Outcomes
Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.
Wednesday, February 13, 2008
IBM Joins Forces with top Cancer Centers
IBM Collaborates with MSKCC, the Molecular Profiling Institute and Sainte-Justine Research Center.
Friday, November 11, 2005
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos